GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Athira Pharma Inc (NAS:ATHA) » Definitions » Goodwill

ATHA (Athira Pharma) Goodwill : $0.00 Mil (As of Dec. 2024)


View and export this data going back to 2020. Start your Free Trial

What is Athira Pharma Goodwill?

A Goodwill is an intangible asset that arises as a result of the acquisition of one company by another for a premium value. The value of a company's brand name, solid customer base, good customer relations, good employee relations and any patents or proprietary technology represent goodwill. Athira Pharma's goodwill for the quarter that ended in Dec. 2024 was $0.00 Mil.


Athira Pharma Goodwill Historical Data

The historical data trend for Athira Pharma's Goodwill can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Athira Pharma Goodwill Chart

Athira Pharma Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Goodwill
Get a 7-Day Free Trial - - - - -

Athira Pharma Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Goodwill Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Athira Pharma Goodwill Calculation

A Goodwill is an intangible asset that arises as a result of the acquisition of one company by another for a premium value. The value of a company's brand name, solid customer base, good customer relations, good employee relations and any patents or proprietary technology represent goodwill. Goodwill is considered an intangible asset because it is not a physical asset like buildings or equipment. The goodwill account can be found in the assets portion of a company's balance sheet.


Athira Pharma  (NAS:ATHA) Goodwill Explanation

Goodwill to Asset ratio measures how much goodwill a company is recording compared to the total level of its assets.

It is calculated by dividing goodwill by total assets.

Athira Pharma's Goodwill-to-Asset Ratio for the fiscal year that ended in Dec. 2024 is calculated as

Goodwill-to-Asset (A: Dec. 2024 )=Goodwill/Total Assets
=0/58.779
=

Athira Pharma's Goodwill-to-Asset Ratio for the quarter that ended in Dec. 2024 is calculated as

Goodwill-to-Asset (Q: Dec. 2024 )=Goodwill/Total Assets
=0/58.779
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

If the goodwill-to-asset ratio increases, it can mean that the company is recording a proportionately higher amount of goodwill, assuming total assets are remaining constant. It is generally good to see a company increasing its assets regularly; however, if these increases are coming from intangible assets, such as goodwill, the increases may not be as good.

Increases in the goodwill-to-asset ratio might suggest that a company has been aggressively acquiring other firms or has seen its tangible assets decrease in value. When a large portion of total assets are attributable to intangible assets (such as goodwill), the company may be at risk of having that portion of its asset base wiped out quickly if it must record any goodwill impairments. Decreases in the goodwill-to-assets ratio suggest that the company has either written down some goodwill or increased its tangible assets.

Asset needs vary from industry to industry. This is why comparing goodwill-to-assets ratios is generally most meaningful among companies within the same industry. By comparing a company's goodwill to assets ratio to those of other companies within the same industry, investors can get a feel for how a company is managing its goodwill.


Athira Pharma Goodwill Related Terms

Thank you for viewing the detailed overview of Athira Pharma's Goodwill provided by GuruFocus.com. Please click on the following links to see related term pages.


Athira Pharma Business Description

Traded in Other Exchanges
N/A
Address
18706 North Creek Parkway, Suite 104, Bothell, WA, USA, 98011
Athira Pharma Inc is a late clinical-stage biopharmaceutical company focused on developing small molecules engineered to restore neuronal health and slow neurodegeneration. Its pipeline candidates are; Fosgonimeton (ATH-1017) is a small molecule drug candidate designed to enhance the activity of the neurotrophic hepatocyte growth factor (HGF) system; ATH-1020 a novel, orally available, next-generation small molecule drug candidate designed to positively modulate the neurotrophic HGF system; ATH-1105 is a novel, orally available, next-generation, small molecule drug candidate designed to positively modulate the neurotrophic HGF system.
Executives
Mark James Litton officer: Chief Operating Officer 11804 NORTH CREEK PARKWAY SOUTH, BOTHELL WA 98011
Mark Worthington officer: General Counsel C/O ATHIRA PHARMA, INC., 18706 NORTH CREEK PARKWAY, SUITE 104, BOTHELL WA 98011
Kevin Church officer: Vice President of Discovery 4000 MASON ROAD, SUITE 300, BOX 352141, SEATTLE WA 98195-2141
Rachel Lenington officer: Chief Technology Officer C/O ATHIRA PHARMA, INC., 18706 NORTH CREEK PARKWAY, SUITE 104, BOTHELL WA 98011
Andrew Gengos officer: See Below 21900 BURBANK BOULEVARD, 3RD FLOOR, WOODLAND HILLS CA 91367
Kelly A Romano director C/O DORMAN PRODUCTS, INC., 3400 EAST WALNUT STREET, COLMAR PA 18915
Perceptive Life Sciences Master Fund Ltd 10 percent owner C/O PERCEPTIVE ADVISORS LLC, 51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003
Grant Pickering director C/O VAXCYTE, INC., 825 INDUSTRIAL ROAD, STE. 300, SAN CARLOS CA 94070
James A Johnson director C/O ZYMOGENETICS, INC., 1201 EASTLAKE AVENUE, SEATTLE WA 98102
Glenna Mileson officer: Chief Financial Officer 4000 MASON ROAD, SUITE 300, BOX 352141, SEATTLE WA 98195-2141
Hans Moebius officer: Chief Medical Officer 4000 MASON ROAD, SUITE 300, BOX 352141, SEATTLE WA 98195-2141
Michael A. Panzara director 733 CONCORD AVENUE, CAMBRIDGE MA 02138
Barbara Kosacz director 3175 HANOVER STREET, PALO ALTO CA 94304
Joseph Edelman director, 10 percent owner C/O PERCEPTIVE ADVISORS LLC, 51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003
Rtw Investments, Lp 10 percent owner 40 10TH AVENUE, 7TH FLOOR, NEW YORK NY 10014